JP2015514115A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514115A5 JP2015514115A5 JP2015504730A JP2015504730A JP2015514115A5 JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5 JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015504730 A JP2015504730 A JP 2015504730A JP 2015514115 A5 JP2015514115 A5 JP 2015514115A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical preparation
- polypeptide
- amino acid
- seq
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
- 229920001184 polypeptide Polymers 0.000 claims description 70
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 70
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 65
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
- 101000893585 Homo sapiens Growth/differentiation factor 2 Proteins 0.000 claims description 37
- 101000695367 Homo sapiens Bone morphogenetic protein 10 Proteins 0.000 claims description 34
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 150000007523 nucleic acids Chemical class 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 claims description 12
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 claims description 9
- 208000007502 anemia Diseases 0.000 claims description 9
- 230000000295 complement effect Effects 0.000 claims description 8
- 238000009396 hybridization Methods 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 3
- 229940123237 Taxane Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261621154P | 2012-04-06 | 2012-04-06 | |
| US61/621,154 | 2012-04-06 | ||
| PCT/US2013/035305 WO2013152213A1 (en) | 2012-04-06 | 2013-04-04 | Methods and compositions for increasing red blood cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144654A Division JP2017190344A (ja) | 2012-04-06 | 2017-07-26 | 赤血球を増加させるための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514115A JP2015514115A (ja) | 2015-05-18 |
| JP2015514115A5 true JP2015514115A5 (enExample) | 2016-06-02 |
| JP6234993B2 JP6234993B2 (ja) | 2017-11-22 |
Family
ID=49301055
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015504730A Expired - Fee Related JP6234993B2 (ja) | 2012-04-06 | 2013-04-04 | 赤血球を増加させるための方法および組成物 |
| JP2017144654A Withdrawn JP2017190344A (ja) | 2012-04-06 | 2017-07-26 | 赤血球を増加させるための方法および組成物 |
| JP2019123059A Withdrawn JP2019156858A (ja) | 2012-04-06 | 2019-07-01 | 赤血球を増加させるための方法および組成物 |
| JP2021077695A Pending JP2021107453A (ja) | 2012-04-06 | 2021-04-30 | 赤血球を増加させるための方法および組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017144654A Withdrawn JP2017190344A (ja) | 2012-04-06 | 2017-07-26 | 赤血球を増加させるための方法および組成物 |
| JP2019123059A Withdrawn JP2019156858A (ja) | 2012-04-06 | 2019-07-01 | 赤血球を増加させるための方法および組成物 |
| JP2021077695A Pending JP2021107453A (ja) | 2012-04-06 | 2021-04-30 | 赤血球を増加させるための方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US9809636B2 (enExample) |
| EP (2) | EP2844272A4 (enExample) |
| JP (4) | JP6234993B2 (enExample) |
| AU (3) | AU2013243388B2 (enExample) |
| CA (1) | CA2869474C (enExample) |
| WO (1) | WO2013152213A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| GB201412290D0 (en) | 2014-07-10 | 2014-08-27 | Cambridge Entpr Ltd | Novel use |
| RS61881B1 (sr) | 2015-04-22 | 2021-06-30 | Biogen Ma Inc | Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića |
| CA2982237A1 (en) | 2015-06-05 | 2016-12-08 | Novartis Ag | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor |
| US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| AU2017296040C1 (en) | 2016-07-15 | 2023-06-22 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| KR20220021207A (ko) * | 2020-08-13 | 2022-02-22 | 주식회사 나이벡 | 이소골 형성 부작용 경감으로 치료효과가 증진된 골형성 단백질-9, 10의 변이체 및 이를 포함하는 약학적 조성물 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0272253A4 (en) | 1986-03-07 | 1990-02-05 | Massachusetts Inst Technology | METHOD FOR IMPROVING GLYCOPROTE INSTABILITY. |
| US5661007A (en) | 1991-06-25 | 1997-08-26 | Genetics Institute, Inc. | Bone morphogenetic protein-9 compositions |
| US6287816B1 (en) | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
| EP0687272B1 (en) * | 1993-03-04 | 2007-01-17 | Stryker Corporation | Method and compositions for recombinant osteogenic protein production |
| US5637480A (en) | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
| DE69433742T2 (de) | 1993-05-12 | 2005-07-07 | Genetics Institute, LLC, Cambridge | Bmp-10 zusammensetzungen |
| US6034062A (en) | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| WO2005113590A2 (en) | 2004-05-12 | 2005-12-01 | Acceleron Pharma Inc. | Bmp10 propeptides and related methods |
| ES2551852T3 (es) | 2004-07-23 | 2015-11-24 | Acceleron Pharma Inc. | Polipéptidos del receptor ActRII |
| WO2006105359A2 (en) | 2005-03-30 | 2006-10-05 | Wyeth | Methods for stimulating hair growth by administering bmps |
| EA201692543A1 (ru) | 2005-11-23 | 2017-08-31 | Акселерон Фарма Инк. | Антагонисты активина-actriia и их применение для стимулирования роста кости |
| GB0615129D0 (en) | 2006-07-29 | 2006-09-06 | Univ Cardiff | Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies |
| EP2468291B1 (en) | 2006-12-18 | 2017-11-22 | Acceleron Pharma, Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| CA2677007A1 (en) | 2007-02-01 | 2008-08-07 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| CA3039330C (en) | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| TWI586364B (zh) | 2008-05-02 | 2017-06-11 | 艾西利羅製藥公司 | 調節血管新生與周圍細胞組成的方法與組合物 |
| CA2724525A1 (en) | 2008-05-15 | 2009-11-19 | Acceleron Pharma, Inc. | Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof |
| NZ590326A (en) * | 2008-06-26 | 2013-05-31 | Acceleron Pharma Inc | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| JP5922928B2 (ja) | 2008-08-14 | 2016-05-24 | アクセルロン ファーマ， インコーポレイテッド | 赤血球レベルを高めるためのｇｄｆトラップの使用 |
| EP2440577A4 (en) | 2009-06-12 | 2013-01-23 | Acceleron Pharma Inc | SHORTEN ACTRIIB FC FUSION PROTEINS |
| ES2796121T3 (es) | 2009-08-13 | 2020-11-25 | Acceleron Pharma Inc | Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos |
| JP2012238811A (ja) | 2011-05-13 | 2012-12-06 | Toshiba Corp | 半導体不揮発性記憶装置およびその製造方法 |
| US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| CN104411720B (zh) * | 2012-07-02 | 2018-05-11 | 协和发酵麒麟株式会社 | 以抗bmp9抗体作为有效成分的、对肾性贫血、癌性贫血等贫血的治疗剂 |
| HK1251157A1 (zh) | 2015-05-13 | 2019-01-25 | 细胞基因公司 | 使用ACTRII配体陷阱治疗β-地中海贫血 |
-
2013
- 2013-03-14 US US13/827,477 patent/US9809636B2/en active Active
- 2013-04-04 CA CA2869474A patent/CA2869474C/en active Active
- 2013-04-04 EP EP13772302.9A patent/EP2844272A4/en not_active Withdrawn
- 2013-04-04 WO PCT/US2013/035305 patent/WO2013152213A1/en not_active Ceased
- 2013-04-04 AU AU2013243388A patent/AU2013243388B2/en not_active Ceased
- 2013-04-04 EP EP17208236.4A patent/EP3351260B1/en active Active
- 2013-04-04 JP JP2015504730A patent/JP6234993B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-26 JP JP2017144654A patent/JP2017190344A/ja not_active Withdrawn
- 2017-10-13 US US15/783,056 patent/US10344066B2/en active Active
-
2018
- 2018-04-03 AU AU2018202326A patent/AU2018202326B2/en not_active Ceased
-
2019
- 2019-05-24 US US16/422,117 patent/US10829534B2/en active Active
- 2019-07-01 JP JP2019123059A patent/JP2019156858A/ja not_active Withdrawn
-
2020
- 2020-10-06 US US17/063,848 patent/US11807673B2/en active Active
-
2021
- 2021-02-24 AU AU2021201196A patent/AU2021201196A1/en not_active Abandoned
- 2021-04-30 JP JP2021077695A patent/JP2021107453A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015514115A5 (enExample) | ||
| Merten et al. | Viral vectors for gene therapy and gene modification approaches | |
| JP2017533910A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP2014513952A5 (enExample) | ||
| JP2015502389A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| JP2015520161A5 (enExample) | ||
| FI3310809T3 (fi) | Anti-cgrp-vasta-aineformulaatio | |
| JP2014503206A5 (enExample) | ||
| WO2015138357A3 (en) | Compositions useful in treatment of otc deficency | |
| JP2015508771A5 (enExample) | ||
| JP2016538885A5 (enExample) | ||
| JP2016506416A5 (enExample) | ||
| JP2012529436A5 (enExample) | ||
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| RU2017101705A (ru) | Фармацевтическая композиция, предназначенная для применения для предупреждения и/или лечения заболевания, которое развивается или прогрессирует вследствие снижения или утраты активности фактора свертывания крови viii и/или активированного фактора свертывания крови viii | |
| RU2015128078A (ru) | Композиции и способы лечения рака мозга | |
| JP2013136622A5 (enExample) | ||
| JP2015514132A5 (enExample) | ||
| MX2014004814A (es) | Compuestos y metodos para mejorar las respuestas inmunes innatas. | |
| EA201400963A1 (ru) | Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью | |
| EA201000085A1 (ru) | dsPHK, ПРЕДНАЗНАЧЕННАЯ ДЛЯ ЛЕЧЕНИЯ ВИРУСНОЙ ИНФЕКЦИИ | |
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli | |
| JP2018509388A5 (enExample) |